SAN FRANCISCO, Aug. 25 /PRNewswire/ — Jennerex, Inc., a
clinical-stage cancer biotherapeutics company, today announced the
appointment of Lara Longpre to the position of chief operating
officer. Ms. Longpre will be responsible for the development of the
company’s lead product, JX-594, as well as Jennerex’s other product
candidates in development and will lead the clinical operations and
research, manufacturing, regulatory and quality functions. Ms.
Longpre has served as a consultant to Jennerex since 2009.
“Lara’s extensive experience in developing therapeutics will
make her a key member of our executive management team,” said David
H. Kirn, M.D., president and chief executive officer of Jennerex.
“Her systematic and meticulous approach to operations, combined
with her demonstrated leadership ability, make Lara the ideal
person to direct the development of JX-594 as we move toward late
stage clinical trials in advanced liver cancer.”
Ms. Longpre brings to Jennerex over 17 years of broad clinical
research, operations, and leadership expertise in all stages of
clinical development. Prior to Jennerex, Ms. Longpre held the
position of senior vice president, clinical and corporate
affairs at MedGenesis Therapeutix and held senior positions at PRA
International, a global CRO, including vice president of proposals
and contracts, vice president of quality and process management,
director of global regulatory affairs, and director of operations.
She has directly managed several pivotal Phase 3 trials, and has
specific expertise in project management, clinical operations, and
quality management systems, including achieving ISO 9001:2000
registration and ensuring Sarbanes-Oxley compliance while at an
international CRO. Ms. Longpre holds an M.Sc. in Medical Science
from Harvard Medical School, an MBA from Queens University, and
B.A. from Cornell University.
Jennerex, Inc. is a clinical-stage biotherapeutics comp